The abstract will be made available on the publications section of the Capricor website.

Detailed price information for Capricor Therap (CAPR-Q) from The Globe and Mail including charting and trades.

In October 2024, Capricor announced positive 3-year safety and efficacy results from its ongoing HOPE-2 open-label extension ...

US biotech Capricor Therapeutics (Nasdaq: CAPR) saw its shares leap more than 31% to $7.82 by mid-morning on positive development for its deramiocel. Capricor said that, following recent meetings with ...

Regenxbio (RGNX) expects its balance in cash, cash equivalents and marketable securities of $278.6M as of September 30, 2024 to fund its operations into 2026. Published first on TheFly – the ...

Capricor Therapeutics (CAPR) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2024. This widely-known consensus ...

The move comes just before a Biden administration deadline for Israel to deliver more aid to the enclave or risk a cutoff of military supplies. By Hiba Yazbek A day after the prime minister of ...

This story was adapted from Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. A slight format change this week.

Why are the two often so disconnected? And what role can technology play in integrating them? A new CMS accountable care program aims to drive progress, and one expert explains what it means for ...

Nov. 11, 2024 — Why is the expansion of our Universe accelerating? Twenty-five years after its discovery, this phenomenon remains one of the greatest scientific mysteries. Solving it involves ...